These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15350573)

  • 1. Pseudoaneurysm of the femoral artery in a HIV-infected man.
    Bongiovanni M; Pisacreta M; Ortu M; Tordato F; Codemo R; Gervasoni C; Gornati R; Trovati S; Piolini R; Chiesa E; Porretta T; Bini T
    Eur J Vasc Endovasc Surg; 2004 Oct; 28(4):451-3. PubMed ID: 15350573
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atazanavir urolithiasis.
    Chang HR; Pella PM
    N Engl J Med; 2006 Nov; 355(20):2158-9. PubMed ID: 17108352
    [No Abstract]   [Full Text] [Related]  

  • 4. Does atazanavir cause lipodystrophy?
    Gazzard BG; Moyle G
    J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
    Sulkowski MS
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S90-7. PubMed ID: 14986280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of renal stones in patients treated with atazanavir.
    Tattevin P; Revest M; Chapplain JM; Ratajczak-Enselme M; Arvieux C; Michelet C
    Clin Infect Dis; 2013 Apr; 56(8):1186. PubMed ID: 23300244
    [No Abstract]   [Full Text] [Related]  

  • 7. [Atazanavir-induced nephrolithiasis].
    Valencia ME; Moreno V
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract]   [Full Text] [Related]  

  • 8. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
    Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
    AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hepatic cytolysis in an HIV-infected patient taking atazanavir.
    Eholié SP; Lacombe K; Serfaty L; Wendum D; Girard PM
    AIDS; 2004 Jul; 18(11):1610-1. PubMed ID: 15238786
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
    Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
    HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
    Turatti L; Sprinz E; Lazzaretti RK; Kuhmmer R; Agnes G; Silveira JM; Basso RP; Pinheiro CA; Silveira MF; de Almeida S; Ribeiro JP; Mattevi VS
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1015-8. PubMed ID: 22050734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
    de Saint-Martin L; Bressollette L; Perfezou P; Bellein V; Ansart S; Vallet S; Pasquier E
    AIDS; 2010 Nov; 24(18):2797-801. PubMed ID: 21063175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to Tattevin et al.
    Hamada Y; Nishijima T; Komatsu H; Gatanaga H; Oka S
    Clin Infect Dis; 2013 Apr; 56(8):1186-7. PubMed ID: 23300233
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
    Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
    HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir: clinical use.
    Bartlett JG
    Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug profile: atazanavir (Reyataz, ATV).
    Pham PA
    Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of different protease inhibitors on coronary heart disease risk.
    Coleman CI; White CM
    Conn Med; 2007 Jan; 71(1):15-7. PubMed ID: 17288101
    [No Abstract]   [Full Text] [Related]  

  • 20. Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose.
    Lanzafame M; Bonora S; Lattuada E; Calcagno A; Di Perri G; Concia E
    AIDS Res Hum Retroviruses; 2014 Sep; 30(9):835-6. PubMed ID: 24998758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.